Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against ADMA Biologics, Inc. Accessibility StatementSkip NavigationMILWAUKEE, March 25, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against ADMA (NASDAQ: ADMA). The investigation results from inaccurate statements ADMA may have made regarding its financial statements, business operations and prospects.Click hereto join our investigation or to obtain additional information, or contact us at [email protec ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma, and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Today, news has broken that Terns Pharmaceuticals, Inc. ( TERN ), a Foster City, California-based biotech, is set to be acquired by the Pharma giant Merck & Co., Inc. ( MRK ), inEdmund Ingham is a biotech consulta ...

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Terns Pharmaceuticals, Inc. (NASDAQ: TERN) Accessibility StatementSkip Navigation 21% more press release views with Request a Demo Click here for more info https://monteverdelaw.com/case/terns-pharmaceuticals-inc/. It is free and there is no cost or obligation to you. NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask: About Monteverde & Associates PC Our firm litigates and has recovered mone ...

Merck Might Have A Fight On Its Hands With Its $6.7 Billion Takeover Of Terns | Investor's Business Daily IPO TRENDS: SpaceX Is Just One Unicorn To Watch Merck (MRK) made plans Wednesday to beef up its cancer treatment portfolio with the $6.7 billion acquisition of Terns Pharmaceuticals (TERN). But the takeover could be at risk. The price tag is low considering the startlingly good data Terns put out for its chronic myeloid leukemia treatment, TERN-701, William Blair analyst Andy Hsieh said. The deal values ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Shareholder Alert: The Ademi Firm investigates whether Terns Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders Accessibility StatementSkip NavigationMILWAUKEE, March 25, 2026 /PRNewswire/ -- Ademi LLP is investigating Terns (NASDAQ: TERN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck.Click hereto learn how to join our investigation and obtain additional information or contact us at [email protected]or toll-free: 866- ...

Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical giant works on beefing up its cancer portfolio before a key patent on its cancer drug Keytruda expires in two years. Merck received accelerated approval for Keytruda from the Food and Drug Administration in September 2014 to treat advanced or unresectable melanoma. The drug has since been approved to treat more than 15 types of cancers and has been a key contributor to Merck's revenu ...

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Terns Pharmaceuticals, Inc. (NASDAQ: TERN) to Merck for $53.00 per share in cash. TERN Stock Alert: Halper Sadeh LLC is Investigating Whether Terns Pha ...

At 7:22 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading hi ...